Keywords: Treatment Response, Cancer
Motivation: Neoadjuvant immunotherapy (nIT) combined with standard chemotherapy is the innovative treatment for esophageal squamous cell carcinoma (ESCC). Some patients may not respond to nIT.
Goal(s): To investigate the value of DWI-derived parameters for the assessment of pathologic response and detection of minimal residual cancer cell (MRC) to nIT.
Approach: The patient population was a sub-cohort from the clinical trial (ClinicalTrials.gov ID: NCT02611700). The pathological response evaluation according to the TRG system proposed by AJCC. DWI-derived parameters including ADC, D, D* and f.
Results: ΔADC and ΔD values were highlighting in assessment of pathologic response and detection of MRC to nIT.
Impact: Nowadays, evaluation of the response to neoadjuvant therapy for cancer mainly relies on the measurement of tumor size according to RECIST. Pseudo-progression with immunotherapy is often observed. fMRI techniques can quantify therapy-induced changes before anatomic variation in tumor size.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords